Perspectives on Clinical Innovation, Patients, and Progress

The inaugural episode of “The Bench 2 Breakthrough Podcast” introduces Acceligen and the vision behind the podcast, hosted by founder and CEO Greg Plunkett alongside co-host Rosa Plunkett. They outline the podcast’s purpose as a platform to share CRO-focused news, industry insights, and practical perspectives on global clinical and regulatory development heading into 2026. The episode explores current challenges facing biotech and pharma, including funding constraints, regulatory delays at the FDA, and workforce impacts in Australia, while highlighting Australia’s efficiency as a pathway to early clinical development. Greg and Rosa also reflect on Acceligen’s 15-year journey, emphasizing patient-centric thinking, agility, and close partnership with biotech clients. The episode closes by inviting listener feedback and previewing future discussions on emerging technologies, regulatory change, and real-world problem solving in drug development.“The Bench 2 Breakthrough Podcast” is the official podcast of Acceligen, created to share real-world insights from the clinical and regulatory front lines of biotech and pharmaceutical development. Hosted by Acceligen founder and CEO Greg Plunkett alongside co-host Rosa Plunkett, the podcast explores global, regional, and local industry news, emerging challenges, and new opportunities shaping the CRO landscape. Each episode blends practical experience with thoughtful discussion, featuring expert guests and perspectives that help sponsors navigate development pathways more efficiently. From early discovery to clinical execution, Bench 2 Breakthrough is about turning scientific progress into meaningful outcomes for patients.Accelagen is a Melbourne-based, award-winning Contract Research Organisation (CRO) specializing in end-to-end clinical trials, regulatory affairs, and biometrics for pharmaceutical and biotechnology companies. Founded in 2010, it supports Phase I-IV trials and offers strategic guidance for drug and medical device development. We believe the future of human health needs a fresh, future-focused approach. We challenge existing conventions to deliver commercially savvy and patient-centric outcomes for leading biopharmaceutical and medical device companies in the fast-growing global trials market across Australia, North America, Asia Pacific, and Europe.